United States of America

United States of America

Streamlines approval and permitting for investment in pharmaceutical manufacturing

05 May 2025

On 5 May 2025, the President of United States of America issued Executive Order 14293 Regulatory Relief to Promote Domestic Production of Critical Medicines to streamline regulatory review and permitting for the construction and expansion of pharmaceutical manufacturing facilities in the United States.

The Executive Order instructs:

  • The Food and Drug Administration to reduce duplicative requirements and improve the speed and predictability of reviews and inspections for new and expanded domestic pharmaceutical manufacturing capacity, including through earlier engagement with manufacturers and updated guidance for certain facility and site changes, including shifts from foreign to domestic production sites; and

  • The Environmental Protection Agency to streamline environmental requirements affecting domestic pharmaceutical manufacturing projects and, where an Environmental Impact Statement is required, to support faster coordinated permitting through lead-agency arrangements and a single applicant point of contact.  

Nature of measure:
  • Facilitation
Type:
  • Entry and establishment (Approval and admission - other)
  • Promotion and facilitation (Investment facilitation )
Industry:
  • Manufacturing (Manufacture of basic pharmaceutical products and pharmaceutical preparations)
Inward FDI:
Yes
Outward FDI:
No
Sources: